BioVie Inc. (NASDAQ:BIVI - Get Free Report) was the recipient of some unusual options trading on Monday. Traders purchased 2,043 call options on the company. This is an increase of 2,661% compared to the average daily volume of 74 call options.
BioVie Stock Up 11.9 %
BIVI traded up $0.28 during trading on Monday, hitting $2.63. The company had a trading volume of 146,808,216 shares, compared to its average volume of 1,136,069. The company has a market capitalization of $160.87 million, a PE ratio of -2.80 and a beta of 0.67. BioVie has a one year low of $1.04 and a one year high of $58.20. The firm's 50-day moving average price is $2.25 and its 200 day moving average price is $1.15.
BioVie (NASDAQ:BIVI - Get Free Report) last issued its quarterly earnings results on Monday, September 30th. The company reported ($6.60) EPS for the quarter.
Hedge Funds Weigh In On BioVie
A hedge fund recently bought a new stake in BioVie stock. CVI Holdings LLC acquired a new stake in BioVie Inc. (NASDAQ:BIVI - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 599,897 shares of the company's stock, valued at approximately $317,000. CVI Holdings LLC owned approximately 1.50% of BioVie at the end of the most recent reporting period. 4.59% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, ThinkEquity initiated coverage on BioVie in a research report on Monday, July 1st. They issued a "buy" rating and a $3.00 price objective for the company.
View Our Latest Stock Report on BioVie
BioVie Company Profile
(
Get Free Report)
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Featured Articles
Before you consider BioVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioVie wasn't on the list.
While BioVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
